New York, May 21, 2026, 13:14 EDT
- AYTU was last quoted at $2.08, down 7 cents, while biotech ETFs were little changed.
- Aytu’s next near-term catalyst is a May 28 investor webcast.
- The stock is still trading off a quarter marked by falling legacy revenue and early Exxua launch costs.
Aytu BioPharma shares slipped about 3% on Thursday, trading at $2.08, as investors waited for management’s next update on the launch of Exxua, its antidepressant, at a virtual investor conference next week. The broader biotech tape was quieter, with the SPDR S&P Biotech ETF and iShares Nasdaq Biotechnology ETF both fractionally lower.
The stock move matters now because Aytu is in a narrow window: Exxua is new enough that every prescription trend counts, but the legacy ADHD and pediatric drug businesses are already shrinking. The company said it will present at the Lytham Partners Spring 2026 Investor Conference on May 28 at 9:15 a.m. Eastern time and hold one-on-one investor meetings.
Aytu reported fiscal third-quarter net revenue of $12.4 million, down from $18.5 million a year earlier. Exxua contributed $2.4 million, while ADHD portfolio sales fell to $9.1 million from $15.4 million and the pediatric portfolio dropped to $0.9 million from $3.1 million. Adjusted EBITDA, a profit measure that removes interest, taxes, depreciation, amortization and certain other items, was a loss of $2.8 million, compared with positive $3.9 million a year earlier.
Chief Executive Josh Disbrow called the early Exxua traction “highly encouraging” and said more than 1,300 prescriptions had been written in the quarter by more than 450 prescribers. That is the core of the bull case. It is also still early.
On the company’s earnings call, Disbrow said Aytu had seen prescriptions in “41 or 42 states,” including places where it had no sales-force presence. Chief Financial Officer Ryan Selhorn was more clipped on the financial shape of the quarter, saying the revenue story was “very much about transition.” Investing
The balance sheet gives Aytu some room, but not endless room. A 10-Q filing showed cash and cash equivalents of $26.7 million at March 31, down from $31.0 million at June 30, 2025; the filing also listed a $10.4 million revolving credit facility balance at quarter-end.
Competition is not theoretical. Exxua is going after major depressive disorder, where Axsome Therapeutics markets Auvelity for adults with MDD, while Johnson & Johnson’s Spravato is used for treatment-resistant depression and certain MDD cases with suicidal thoughts or actions. Aytu also has to win against cheap generic antidepressants that are already embedded in prescribing habits.
The risk is that the launch curve does not steepen fast enough. Aytu has already flagged normal early-launch noise around coverage, gross-to-net dynamics — the gap between billed sales and what the company keeps after rebates, discounts and other deductions — and pharmacy ordering patterns. Its filings also warn that the business operates in a competitive and rapidly changing environment and that actual results can differ from management projections.
For now, the stock is trading like a small-cap drug launch story with limited margin for error. The May 28 webcast is unlikely to settle the Exxua question, but investors will be listening for any fresh detail on refill activity, payer access and whether management can fund the push without leaning too hard on shareholders.
